What Is the Success Rate of Heart Valve Replacement Surgery?

Heart valve replacement surgery has a strong track record, with roughly 95 out of 100 patients surviving the operation and the immediate postoperative period for standard aortic valve replacement. Long-term outcomes are also encouraging: five-year survival rates generally land between 80% and 90%, depending on the patient’s age and overall health. But “success rate” is a deceptively simple phrase for a procedure whose outcomes vary dramatically based on which valve is being replaced, what kind of prosthesis goes in, how old the patient is, and what other health conditions are in the mix.

Short-Term Survival After Surgery

The number most people want first is the chance of surviving the operation itself. For aortic valve replacement, the benchmark 30-day mortality rate in large surgical series runs around 3% to 5%. One study of over 1,200 patients reported a 30-day mortality of about 5%, with the strongest predictors of early death being poor heart-pumping function, active infection of the valve, emergency surgery, and prolonged time on the heart-lung machine.¹ For patients in their 80s, the risk is higher: one series of 245 octogenarians found a 30-day mortality of 9%.²

Kidney function turns out to be one of the most powerful factors influencing whether someone survives the hospital stay. In a large analysis, in-hospital mortality climbed from about 3% in patients with normal kidney function to nearly 16% in those with severe kidney disease, and over 17% in patients on dialysis.³ That five-fold difference underscores why surgeons weigh kidney health so heavily when deciding whether to operate.

Long-Term Survival

Getting through surgery is only half the picture. A large Swedish registry tracking over 33,000 patients who underwent surgical aortic valve replacement found that about 43% had died by a mean follow-up of just over seven years. At the 10-year mark, the cumulative death rate from all causes was around 43%, and at 20 years it was roughly 79%. Cardiovascular disease accounted for the largest share of those deaths, followed by cancer and other causes.⁴ These figures include elderly patients and those with significant health problems, so they reflect real-world outcomes rather than best-case scenarios.

For middle-aged patients, the outlook is somewhat better. A Korean national dataset focusing on patients aged 50 to 69 found five-year survival around 88% to 91% and ten-year survival around 75% to 77%, regardless of whether they received a mechanical or bioprosthetic valve.⁵ These numbers are reassuring, though they also reflect a population that was, on average, healthier than the typical valve surgery candidate in Western countries.

How Age and Health Conditions Shape Your Risk

No single statistic captures your personal odds. Among high-risk elderly patients in the United States, severe lung disease and kidney failure each cut median survival roughly in half compared with patients without those conditions. A weakened heart or a previous heart operation was associated with about a 25% reduction in median survival.⁶

A more recent study of mitral valve surgery patients illustrates how dramatically risk can vary. After sorting patients into four tiers based on age and comorbidities, the one-year death rate ranged from under 4% in the lowest-risk group all the way to nearly 28% in the highest-risk group.⁷ Factors that pushed patients into higher risk categories included age over 75, chronic lung disease, heart failure, prior heart attack, prior stroke, and liver or kidney disease. In other words, two patients undergoing the same operation can have wildly different chances of survival depending on what other medical baggage they bring to the table.

Does It Matter Which Valve Is Being Replaced?

Yes, and the differences are substantial. Aortic valve replacement is the most commonly studied and generally carries the best outcomes. Mitral valve replacement runs a close second, but long-term survival after mitral replacement tends to be somewhat worse than after aortic replacement. A study comparing the two valve positions in patients under 60 found that mitral valve replacement was associated with about a 40% higher long-term death rate compared with aortic valve replacement.⁸

Tricuspid valve replacement is less common and carries notably higher risk. Historical data put the operative mortality somewhere between 10% and 16%, with five-year survival around 73% to 79% and ten-year survival dropping to roughly 47% to 49%.⁹¹⁰ Part of the reason for worse outcomes is that tricuspid disease often occurs alongside other valve problems or in patients with advanced heart failure, making the surgery more complex and the patient sicker to begin with.

Mitral Valve Repair Versus Replacement

When the mitral valve is the problem, surgeons often prefer repair over replacement. A propensity-matched comparison found that patients who had their mitral valve repaired had roughly half the death rate of those who had it replaced, even when the replacement preserved key structures of the valve apparatus.¹¹ The trade-off is that repaired valves sometimes fail and need a second operation more often than replaced valves do.

That survival advantage does not always hold up. A randomized trial of patients with severe mitral regurgitation caused by coronary artery disease found no significant difference in death rates between repair and replacement at 12 months. However, more than 30% of the repair patients had the leaking come back at moderate-to-severe levels within a year, compared with about 2% in the replacement group.¹² The picture here is genuinely muddled: repair is generally preferred because of its survival edge in most populations, but for certain causes of mitral disease, replacement delivers a more durable fix.

Mechanical Versus Bioprosthetic Valves

After deciding to replace a valve, the next big choice is what to put in. Mechanical valves are built to last a lifetime but require lifelong blood-thinning medication. Bioprosthetic (tissue) valves come from animal tissue or human donors, do not require permanent blood thinners, but wear out over time. The general guideline is that patients younger than about 60 to 65 lean toward mechanical valves for their durability, while older patients tend to receive bioprosthetic valves to avoid the risks of lifelong anticoagulation.¹³

In terms of survival, the two types perform similarly. A long-term study of patients under 60 found no survival difference between tissue and mechanical prostheses in either the aortic or mitral position over 20 years of follow-up.⁸ However, reoperation rates were significantly higher for tissue valve recipients over the long haul, which makes sense given that biological valves degrade.¹⁴ By 20 years, roughly 89% of patients who received a tissue aortic valve and 84% of those who received a tissue mitral valve had needed a reoperation.⁸

The flip side of choosing a mechanical valve is that anticoagulation carries its own dangers. In a nationwide study, major bleeding occurred at a rate of about 2.6 per 100 patient-years for mechanical aortic valve recipients and 3.9 per 100 patient-years for mechanical mitral valve recipients.¹⁵ Blood clots still occurred despite anticoagulation, at about 1.3 to 1.6 strokes or clot events per 100 patient-years. These numbers accumulate over decades, which is exactly why older patients tend to avoid the mechanical route.

Open Surgery Versus Catheter-Based Replacement

For aortic valve disease, patients now have a second option: transcatheter aortic valve replacement, commonly known as TAVR. Instead of opening the chest, surgeons thread a compressed replacement valve through a large blood vessel and deploy it inside the old valve. TAVR was initially reserved for patients too sick for open surgery, but it has expanded to lower-risk populations.

A meta-analysis comparing the two approaches found that 30-day mortality was similar, with TAVR at about 2.5% and surgical replacement at about 3%.¹⁶ TAVR showed advantages in major bleeding (about 11% versus 31%) and new atrial fibrillation (about 2% versus 50%), along with lower rates of stroke and acute kidney injury. A matched comparison in low-risk patients found three-year survival was essentially the same for both approaches, at roughly 86% versus 88%.¹⁷

There is an important caveat, though. A separate meta-analysis found that while short-term results favored TAVR, long-term mortality was slightly higher with the catheter-based approach in some analyses.¹⁸ Questions remain about how long TAVR valves last compared with surgically implanted ones, and what happens when a catheter-placed valve eventually fails. For younger patients who may outlive their prosthesis, that uncertainty is a real consideration.

Complications Beyond Mortality

Surviving surgery is not the only measure of success. Stroke is one of the most feared complications. One prospective study using detailed neurological testing found clinical strokes in 17% of aortic valve surgery patients, though most were mild. Moderate or severe strokes occurred in about 4% and were strongly linked to in-hospital death.¹⁹ That 17% figure is higher than the rates typically recorded in surgical databases, which suggests many mild strokes go undetected without specialized screening. A single-center report found a stroke rate of about 4% among its valve surgery patients and identified combined multi-valve procedures as a particularly strong risk factor.²⁰

Another common complication is the need for a permanent pacemaker afterward, which happens when the surgery damages the heart’s electrical wiring. Patients who needed a pacemaker after surgical aortic valve replacement had a modestly higher risk of death and a substantially higher risk of hospitalization for heart failure over the long term compared with those who did not.²¹

Prosthetic valve endocarditis, an infection of the new valve, is uncommon but devastating. Data from the PARTNER trials found that when it did occur, it was strongly associated with death.²² A Finnish registry reported a one-year mortality of over 50% among patients who developed prosthetic valve endocarditis, with staphylococcal bacteria being the most common culprit.²³ This is why patients with prosthetic valves are advised to take antibiotics before certain dental and medical procedures.

Quality of Life After Surgery

For many patients, the real question is not “Will I survive?” but “Will I feel better?” The evidence here is encouraging. By 18 months after aortic valve replacement, quality-of-life scores in both mechanical and tissue valve recipients improved to levels comparable to the general population, with no meaningful difference between valve types.²⁴

Cardiac rehabilitation after surgery boosts exercise capacity and helps patients return to work.²⁵ A randomized trial found that patients who started structured rehab early achieved measurably better physical capacity at hospital discharge and at six months, and that improvement in physical function after discharge actually predicted lower follow-up mortality.²⁶ That said, cardiac rehab primarily improves physical fitness rather than mental health. A separate randomized trial showed clear gains in peak oxygen uptake at four months but no improvement in mental health scores.²⁷ Patients dealing with anxiety or depression after heart surgery may need specific psychological support rather than relying on exercise alone.

When a Replacement Valve Needs Replacing

Bioprosthetic valves degrade over time, which means many patients eventually face a second operation. Reoperation carries higher risk than the first surgery, but perhaps less than many patients fear. A UK national registry spanning 23 years found that elective redo aortic valve surgery had a mortality of about 5%, and mortality trends improved over the study period.²⁸ A smaller single-center series reported an early mortality of about 10% for repeat aortic valve surgery, with female sex, coronary artery disease, and impaired kidney function serving as independent predictors of death.²⁹ The gap between those two figures reflects the difference between elective, planned reoperations and the broader mix that includes urgent cases. Planning a redo before the old valve fails catastrophically makes a meaningful difference in outcomes.

Where You Have Surgery Matters

Surgical volume — how many of these operations a hospital and surgeon perform each year — is one of the most consistent predictors of outcome. A U.S. study of mitral valve surgery found that higher hospital and surgeon volumes were associated with lower 30-day mortality and fewer complications.³⁰ For aortic valve replacement specifically, a landmark analysis published in the New England Journal of Medicine found that the surgeon’s personal volume accounted for the entire hospital-volume effect on mortality — meaning a high-volume surgeon at a low-volume hospital outperformed a low-volume surgeon at a high-volume hospital.³¹ If you have any choice in where to have valve surgery, the individual surgeon’s experience may matter more than the institution’s name.

Risk Scores and How Surgeons Estimate Your Odds

Before any valve operation, your surgical team will calculate a predicted mortality using one of several scoring systems, most commonly the STS score (from the Society of Thoracic Surgeons) or the EuroSCORE II. These calculators take your age, kidney function, lung health, heart function, and a dozen other variables and produce a percentage that estimates your chance of dying within 30 days of surgery. The STS score has generally shown the best ability to discriminate between patients who die and those who survive.³² That said, both scores can over- or under-predict depending on the population. One multicenter study in China found that the EuroSCORE II overpredicted mortality while the STS score underpredicted it, and both performed poorly for patients undergoing surgery on multiple valves at once.³³ Treat these numbers as a starting point for conversation with your surgeon rather than a verdict.

Sex Differences in Outcomes

Women and men do not have identical outcomes after valve replacement, and the pattern depends on the type of valve implanted. After receiving a bioprosthetic aortic valve, women had significantly better long-term survival than men and a lower rate of reoperation. But with a mechanical aortic valve, women faced a higher risk of late stroke, and the survival advantage disappeared.³⁴ A more recent study of TAVR patients from Sweden confirmed the pattern: women had lower cumulative mortality than men at one, five, and ten years, with an absolute survival difference of about 6% at the ten-year mark. Women also had lower rates of major bleeding, though stroke, heart attack, and heart failure rates were similar between sexes.³⁵ The reasons for this female survival advantage are not fully understood but likely involve differences in the types of heart disease that lead to valve problems, as well as hormonal and vascular biology factors.

Valve Surgery in Children

Pediatric heart valve replacement is a different challenge altogether. Children’s hearts are still growing, and no currently available prosthetic valve grows with them. Biological valves are generally preferred in children to spare them from lifelong anticoagulation, but those valves degrade faster in younger patients, virtually guaranteeing multiple reoperations over a lifetime.³⁶ This creates a difficult calculus for families and surgeons: accept the bleeding risks of a mechanical valve and the burden of anticoagulation in an active child, or plan for a series of surgeries as tissue valves wear out. Newer approaches including tissue-engineered valves and specially designed growth-accommodating prostheses are under investigation, but none has yet solved the fundamental problem of implanting a fixed-size device in a growing body.